Compare IDEXX Laboratories, Inc. (IDXX) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Match Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Match Group Inc trades at $39.02 (market cap $9.10B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.9× Match Group Inc's market cap, and Match Group Inc pays a 2.05% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MTCH | |
|---|---|---|
Market Cap | $44.48B | $9.10B |
Sector | Health | Media |
52-Week High | $766.68 | $40.29 |
52-Week Low | $520.87 | $28.90 |
Enterprise Value | $45.38B | $12.05B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
MTCH trades at $38.75, down 1.02% today, near the analyst low target of $38.00. The stock shows a bullish technical signal with strong moving average support, while oscillators remain neutral. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Revenue growth is stable at $3.5B annually, with net income margins improving to 17.59% in 2025. Positive news highlights Tinder's turnaround efforts and Hinge's growth, with a dividend scheduled for July 2026.
Outlook is cautiously optimistic with a consensus price target of $41.63, implying ~7% upside. Strengths include high gross margins (73.8%) and consistent cash flow growth. Risks involve high debt ($3.85B) and Tinder's user declines offset by pricing. Analyst sentiment is bullish (53% Buy), but execution on user engagement remains critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
